9 news items
Evaluating Amicus Therapeutics: Insights From 6 Financial Analysts
FOLD
14 May 24
0
Analysts provide deeper insights through their assessments of 12-month price targets, revealing
This Boston Beer Analyst Turns Bullish; Here Are Top 5 Upgrades For Today.
EIX
FOLD
FTRE
14 May 24
to Buy and increased the price target from $335 to $360. Boston Beer shares declined 2.5% to close at $283.82 on Monday
Guggenheim Upgrades Amicus Therapeutics to Buy, Announces $13 Price Target
FOLD
14 May 24
Guggenheim analyst Debjit Chattopadhyay upgrades Amicus Therapeutics (NASDAQ:FOLD) from Neutral to Buy and announces $13 price target.
UBS Maintains Buy on Amicus Therapeutics, Lowers Price Target to $19
FOLD
10 May 24
UBS analyst Karl Chalabala maintains Amicus Therapeutics (NASDAQ:FOLD) with a Buy and lowers the price target from $20 to $19.
Morgan Stanley Maintains Overweight on Amicus Therapeutics, Lowers Price Target to $19
FOLD
10 May 24
Morgan Stanley analyst Jeffrey Hung maintains Amicus Therapeutics (NASDAQ:FOLD) with a Overweight and lowers the price target from $20 to $19.
abj6ov
FOLD
10 May 24
B of A Securities analyst Tazeen Ahmad maintains Amicus Therapeutics (NASDAQ:FOLD) with a Buy and lowers the price target from $14 to $13.
hauu50quqqnpg2zi688x6qpni7tz
BNTX
FOLD
GSK
26 Mar 24
(NASDAQ:BNTX), where the Group used its proprietary antibody discovery platforms to discover two undisclosed targets for BioNTech's preclinical
p5yocm7j21u6xq4l ofzdjnhk32qev5fjj6xmlzq997jql
FOLD
18 Mar 24
JP Morgan analyst Anupam Rama maintains Amicus Therapeutics (NASDAQ:FOLD) with a Overweight and lowers the price target from $21 to $19.
6wtf9tuiys4qnhbm14zxj2ztw92xv65w5zps3iead1t
FOLD
29 Feb 24
Cantor Fitzgerald analyst Kristen Kluska reiterates Amicus Therapeutics (NASDAQ:FOLD) with a Overweight and maintains $22 price target.
- Prev
- 1
- Next